| Trial ID: | L6532 |
| Source ID: | NCT00396071
|
| Associated Drug: |
Vildagliptin
|
| Title: |
Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: vildagliptin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in C-peptide IAUC (0-4hr), 2 weeks after treatment | Secondary: Change in insulin secretion rate (ISR) relative to glucose (0-2hr), after 2 weeks of treatment|Change in postprandial C-peptide, after two weeks of treatment|Change in postprandial insulin, after two weeks of treatment|Change in postprandial glucagon, after two weeks of treatment|Change in postprandial GLP-1, after 2 weeks of treatment
|
| Sponsor/Collaborators: |
Sponsor: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
22
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-10
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-18
|
| Locations: |
Diabetes Zentrum Bad Lauterberg, Bad Lauterberg, 37431, Germany|Novartis Pharmaceuticals, Basel, Switzerland
|
| URL: |
https://clinicaltrials.gov/show/NCT00396071
|
